The higher number of significant concurrently mutated genes in other molecular pathways may explain the decreased efficacy of PARP inhibitors in prostate cancer harboring BRCA1 mutations compared to those with BRCA2 mutation. The gene discussed is BRCA1; the disease is prostate carcinoma.